Grant: Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
University of Calgary
$90,290.00
The role of reciprocal PD-1/PD-L1 signals between iNKT and dendritic cells in tolerance induction
FY 2008-09
Summary
A few signal pathways may critically regulate immunity. One of such pathway is mediated by Program Death-1 (PD-1) and its ligand PD-L1, since their interactions alter anti-viral and anti-tumor immune responses and are important for self tolerance. However, the mechanism underlying PD-1/PD-L1 mediated immune regulation remains to be defined. We have found recently that iNKT cells, a small subset of white blood expressed very high levels of PD-1 when repetitively stimulated by their ligand, a chemical compound called alpha-GalCer. Ligand stimulation of iNKT cells requires another small subset of white blood cells called dendrtic cells (DCs) that present alpha-GalCer to iNKT cells. Interestingly, these DCs expressed very high levels of PD-L1 shortly after engaging with iNKT cells in the presence of alpha-GalCer. Since alpha-GalCer treatment can effectively prevents type 1 diabetes (T1D) and other autoimmune disorders in animal models, we propose that interactions of PD-1 and PD-L1 between iNKT cells and DCs are important for immune regulation. Both iNKT cells and DCs are critical players in initiating and eliciting immune responses; however, the reciprocal PD-1/PD-L1 signals may switch these cells from immunogenic to tolerogenic. Hence those DCs expressing high levels of PD-L1 inhibit T1D pathogenesis by inducing antigen specific tolerance. We will test this hypothesis by blocking PD-1/PD-L1 interactions during ligand (alpha-GalCer) stimulation to determine if such blockade eliminates the inhibitory effects of alpha-GalCer treatment on autoimmune diabetes in an animal model. We will also test the possibility of switching DCs activated by inflammation from immunogenic to tolerogenic through PD-L1 engagement. The outcome of this study may identify novel therapeutic targets at molecule level, and may be significant for development of islet transplantation protocols that can protect transplanted islets in T1D patients from the attack by established autoimmunity.
Department
Program
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
183465
Name
Yang Yang
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Immunology & Transplantation
Projecttitle
The role of reciprocal PD-1/PD-L1 signals between iNKT and dendritic cells in tolerance induction
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$90,290
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Keyworddelim
Dendritic Cells; Diabetes; Immune Regualtion; Tolerance Induction
Abstract
A few signal pathways may critically regulate immunity. One of such pathway is mediated by Program Death-1 (PD-1) and its ligand PD-L1, since their interactions alter anti-viral and anti-tumor immune responses and are important for self tolerance. However, the mechanism underlying PD-1/PD-L1 mediated immune regulation remains to be defined. We have found recently that iNKT cells, a small subset of white blood expressed very high levels of PD-1 when repetitively stimulated by their ligand, a chemical compound called alpha-GalCer. Ligand stimulation of iNKT cells requires another small subset of white blood cells called dendrtic cells (DCs) that present alpha-GalCer to iNKT cells. Interestingly, these DCs expressed very high levels of PD-L1 shortly after engaging with iNKT cells in the presence of alpha-GalCer. Since alpha-GalCer treatment can effectively prevents type 1 diabetes (T1D) and other autoimmune disorders in animal models, we propose that interactions of PD-1 and PD-L1 between iNKT cells and DCs are important for immune regulation. Both iNKT cells and DCs are critical players in initiating and eliciting immune responses; however, the reciprocal PD-1/PD-L1 signals may switch these cells from immunogenic to tolerogenic. Hence those DCs expressing high levels of PD-L1 inhibit T1D pathogenesis by inducing antigen specific tolerance. We will test this hypothesis by blocking PD-1/PD-L1 interactions during ligand (alpha-GalCer) stimulation to determine if such blockade eliminates the inhibitory effects of alpha-GalCer treatment on autoimmune diabetes in an animal model. We will also test the possibility of switching DCs activated by inflammation from immunogenic to tolerogenic through PD-L1 engagement. The outcome of this study may identify novel therapeutic targets at molecule level, and may be significant for development of islet transplantation protocols that can protect transplanted islets in T1D patients from the attack by established autoimmunity.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yang, Yang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $90,290~ $0~